66 results about "Heart atrium" patented technology

Implantable medical device for stimulating a heart includes a proximal electrode pole, and first and second distal electrode poles. During operation, the device performs: a) detecting an intrinsic atrial contraction of the heart; b) detecting an intrinsic ventricular contraction of the heart; c) determining a first intrinsic atrioventricular conduction time between i) the intrinsic atrial contraction or the stimulation of the atrium and ii) the intrinsic ventricular contraction detected with the first distal electrode pole; and determining a second intrinsic atrioventricular conduction time between i) the intrinsic atrial contraction or the stimulation of the atrium and iii) the intrinsic ventricular contraction detected with the second distal electrode pole; d) setting a stimulated atrioventricular conduction time for stimulating the ventricle of the heart with the first and / or second distal electrode poles, the stimulated atrioventricular conduction time being shorter than the shorter of the first and second intrinsic atrioventricular conduction times.

The present disclosure relates to a device assembly and a method for treating heart failure by normalizing elevated blood pressure in the left atrium of a heart of a mammal. Disclosed herein is a transcatheter interatrial septum excision device assembly configured to create a sized interatrial aperture between the right and left atria of a heart for the relief of elevated left atrial pressure. The device assembly comprises a delivery catheter, a tissue stabilizer attached to a first catheter having a central lumen and a penetrating tip that permits passage of a guidewire, and a cutter attached to a second catheter having a central lumen that permits passage of the first catheter. Alternative configurations comprise a (third) catheter having a central lumen that permits passage of the aforementioned components to and from the right atrium, a tissue retention mechanism and an optional coaxial alignment mechanism.

This invention discloses a method for preparing a simulated heart model and the simulated heart model itself. The method for preparing the simulated heart model includes: dividing a digital heart model into two parts along its coronal plane; preparing corresponding molding molds according to the structural characteristics of the two parts, each molding mold including an outer molding mold and an inner cavity molding mold; applying silicone to the molding surfaces of the outer molding mold and the inner cavity molding mold to form the endocardium and epicardium; applying silicone to the portion of the inner cavity molding mold used for molding the valve to form the valve; assembling the outer molding mold and the inner cavity molding mold to form a cavity; sequentially injecting silicone of corresponding hardness into the regions of the cavity used for molding the atrial myocardium, interatrial septal myocardium, ventricular myocardium, and interventricular septal myocardium to form heart model halves; and bonding the heart model halves corresponding to the two molding molds together to obtain the simulated heart model.

Methods and devices for transvascular prosthetic chordae tendinea implantation are disclosed. A catheter is advanced into the left atrium. From an atrium side, a leaflet connector carried by a distal end of the catheter can be anchored to a superior surface of a mitral valve leaflet. A needle is axially advanceable through the leaflet connector and through the leaflet. A leaflet anchor having a leaflet suture can be advanced out of the needle to secure the mitral valve leaflet to the leaflet suture. A ventricular anchor is anchored to the wall of the ventricle to secure the ventricular wall to a ventricle suture. The leaflet suture and the ventricle suture may be tensioned and connected by a suture lock to form an artificial chordae.

This application relates to a head electrode assembly and an ablation catheter. The head electrode assembly is disposed at the distal end of the catheter assembly of the ablation catheter. The head electrode assembly includes a tip, a pressure sensor, and a limiting member. The tip has a receiving space extending axially to the proximal end face of the tip, and the tip is used to release ablation energy. The pressure sensor is located in the receiving space and at least axially abuts against the tip to detect external pressure on the tip. The pressure sensor is configured to sense at least one of the axial pressure and radial pressure on the tip. The limiting member is disposed at the tip, and the limiting member and the tip are configured to at least jointly limit the axial displacement of the pressure sensor. The pressure sensor can sense the contact pressure between the tip and the tissue, reducing the occurrence of excessive contact force between the tip and the tissue, thereby reducing tissue damage and lowering the risk of damage to the atrial wall and adjacent tissues; it also helps to reduce the occurrence of insufficient contact force between the tip and the tissue, leading to poor contact between the tip and the tissue.

This document describes systems and methods for cardiac monitoring and treatment using left atrial pressure. In many ways, an implantable pressure sensor in the patient's left atrium records a pressure signal. This left atrial pressure allows the calculation of the atrioventricular ratio (AVR), which is clinically relevant and can be used to guide treatment or as part of an open- or closed-loop automated treatment system.

A cardiac treatment device, including:stimulation circuitry configured to generate a non-excitatory electrical signal which, when applied to ventricular tissue during a ventricular refractory period thereof improves a condition of heart failure in human patients;atrial arrhythmia detection circuitry; anddecision circuitry which controls the stimulation circuitry to delivery said signal, also when said atrial arrhythmia detection circuitry detects an atrial arrhythmia.

A method of sensing a physiological parameter involves advancing a delivery catheter to a right atrium of a heart of a patient via a transcatheter access path, advancing the delivery catheter through an atrial septal wall into a left atrium of the heart, deploying a distal anchor of a sensor implant device from the delivery catheter, anchoring the distal anchor of the sensor implant device to a first pulmonary vein, withdrawing the delivery catheter from the first pulmonary vein, thereby exposing at least a portion of a sensor module of the sensor implant device in the left atrium, deploying a proximal anchor of the sensor implant device from the delivery system, anchoring the proximal anchor of the sensor implant device to a second pulmonary vein, and withdrawing the delivery catheter from the heart.

Various embodiments of the present invention comprise a single-chamber collapsible and expandable prosthetic valve implant device with an elevated valve section and comprising the following capabilities: (1) preservation of native valve functionality; (2) initial preservation of native valve functionality with subsequent full replacement of native valve functionality; (3) full replacement of native valve functionality; and / or (4) mitigation of the prolapsing distance of the dysfunctional leaflets by preventing the anterior excursion of the prolapsing leaflets above the upper annular surface and into the left atrial chamber in order to preserve native leaflet functionality for as long as possible. The expanded and implanted device does not extend beyond the boundaries of the subject heart chamber, e.g., the left atrium, thereby enabling the preservation of any remaining native valve functionality with subsequent full replacement of native valve functionality if and when needed.

This application relates to a coronary sinus and left atrium shunt system, belonging to the field of medical device technology. The system described in this application, by setting up a puncture component and a shunt component including a cutter, allows for the cutting of a portion of myocardial tissue between the coronary sinus and the left atrium, forming a shunt orifice. This establishes a shunt channel between the coronary sinus and the left atrium, effectively avoiding the embolism risk associated with atrial septal shunts and improving coronary artery blood perfusion, potentially benefiting myocardial recovery.

Devices, systems, and methods for causing retrograde oxygenated blood flow in at least a portion of the venous system of the myocardium are disclosed. Devices and methods include a method for causing retrograde oxygenated blood flow in at least a portion of the venous system of the myocardium, the method comprising: implanting a variable occluder in a coronary sinus region proximate a left atrium, wherein the variable occluder is configured to gradually increase a level of blood flow restriction over a period of days to enable a venous system of the myocardium to compensate for increased pressure caused by the gradual increase in the level of blood flow restriction; and following venous system compensation, shunting oxygenated blood flow into the coronary sinus to cause retrograde flow of oxygenated blood in at least a portion of the venous system of the myocardium to thereby enable revascularization of the myocardium.

The application relates to a semi-supervised medical image segmentation method based on double-view complementary consistency, which only uses a small amount of labeled medical image data to mine potential feature information in a large amount of unlabeled data to improve the segmentation model performance, and comprises the following steps: a feature space distillation mechanism is used to extract and transfer multi-scale semantic features through a teacher-student model; a double-view fusion strategy is used to optimize pseudo labels and optimize the learning effect of the model on unlabeled data; and an uncertainty estimation method assisted by a pre-trained autoencoder is used to optimize the reliability and segmentation precision of the model. Experimental results on a left atrium (LA) and liver tumor segmentation (LiTS) dataset show that the method achieves good effects in terms of segmentation precision and model robustness.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The application relates to the field of medical devices, in particular to a heart implant, which comprises an anti-reflux prosthesis, a fixing member and a limiting member, the anti-reflux prosthesis is anchored on atrial tissue through the fixing member, one end of the limiting member is connected with the anti-reflux prosthesis, and the other end of the limiting member is fixed on apical tissue, the anti-reflux prosthesis comprises a closing aid and a barrier, the distal end of the barrier is fixed on the middle region of the closing aid, the proximal end of the barrier is connected with the limiting member, and the proximal end part of the closing aid is free; the application not only can increase the coaptation area with adjacent native leaflets to achieve ideal repair effect, but also can avoid the closing aid from floating into the atrium, and has good clinical significance.

An apparatus, system, and method for creating a shunt between a right atrium and a left atrium of a patient's heart. An apparatus includes a shielding structure, a tube proximal to the shielding structure, and an actuating mechanism at a proximal end of the tube. The tube is configured to pass through a lumen of a steerable catheter. The actuating mechanism is for deploying the shielding structure through the tube. The shielding structure is configured for passing through an opening in an atrial septum from the right atrium to the left atrium, and for being retracted in a proximal direction to contact the atrial septum for shielding a proximity of the opening from blood flow in the left atrium to facilitate cryoablation of the opening from the right atrium.

The present technology is directed to adjustable interatrial shunting systems that selectively control blood flow between the left atrium and the right atrium of a patient. The adjustable interatrial devices include a shunting element having an outer surface configured to engage native tissue and an inner surface defining a lumen that enables blood to flow from the left atrium to the right atrium when the system is deployed across the septal wall. The systems can include an actuation assembly for selectively adjusting a geometry of the lumen and / or a geometry of a lumen orifice to control the flow of blood through the lumen.

A computer device for processing cardiac signals comprises: - a data storage (114) arranged to receive input data sets each comprising a plurality of P wave segments each associated with an electrocardiogram track and with an acquisition time window, and a plurality of coronary sinus signals associated with the same acquisition time window and having one or more activation sequence, - an input module comprising a plurality of classifiers, each associated with a respective atrial tachycardia class and arranged to receive an input data set, and to return a value indicating the probability that the input data set indicates an atrial tachycardia which belongs to the associated atrial tachycardia class, each classifier being further associated with a respective confusion matrix, said atrial tachycardia classes being arranged into a hierarchy made of layers each comprising one more node, each node of a given layer being connected to at least one other node in the hierarchy, only part in the layer immediately above and / or in the layer immediately below said given layer in said hierarchy, - a Bayesian engine comprising a prevalence matrix for pair of classifiers which atrial tachycardia classes are connected in said atrial tachycardia class hierarchy, arranged to receive a set of assessments comprising an atrial tachycardia class probability for each classifier, and to process said set of assessments according to the confusion matrices associated with the classifiers and according to said prevalence matrices in order to determine an updated set of assessments which maximizes the expression (I), where Z i are the updated set of assessments values, Y i are the set of assessments, YC i represents the states of the child nodes of the classifier associated with Y i in said atrial tachycardia class hierarchy, and N is the total number of classifiers, said device being arranged to receive an input data set, to process it with the input module, to derive therefrom a set of assessments provided to said Bayesian engine, and to return one or more atrial tachycardia information derived from said updated set of assessments.

This application discloses a testing system and method for artificial heart valve implants, relating to the field of medical device testing technology. The system includes: a ventricular simulator, an atrial simulator, a highly transparent and compliant valve testing chamber containing an artificial heart valve, a vascular compliance simulator, and a vascular damping simulator forming a circulation loop, a high-speed camera, and a laser generator. The circulation loop simulates the blood flow environment of the artificial heart valve, with a tracer particle suspension added to the flow medium. The ventricular simulator, atrial simulator, vascular damper, and vascular compliance simulator provide power, storage space, resistance, and pulse pressure to the flow medium, respectively. The laser generator and high-speed camera work together to acquire particle images after implantation of the artificial heart valve. The particle images are uploaded to a computer for visual analysis of the heart valve pulsating flow field based on digital particle image velocimetry technology, thereby enabling quantitative analysis of the risk after implantation at the intended site.

The application discloses a kind of near-field coherent heart radio frequency sensing method and system based on code division multiple access, comprising: 4-way frequency f synchronous baseband signal is configured, 4-way synchronous chip is configured, synchronous baseband signal is multiplied with corresponding synchronous chip to modulate, and 4-way digital baseband signal is obtained;4-way digital baseband signal is handled to obtain 4-way heart measurement signal;4-way heart measurement signal is respectively transmitted to corresponding antenna by radio frequency transceiver and is emitted;The antenna is respectively arranged in left ventricle, left atrium, right ventricle, right atrium;Antenna receives reflected signal, and is recorded as heart sensing signal;Heart sensing signal is transmitted to radio frequency transceiver, and after processing, the baseband signal containing heart chamber beat information is obtained;The baseband signal containing heart chamber beat information is multiplied with corresponding synchronous chip to demodulate, band-pass filter, and the demodulation signal corresponding to heart chamber beat information is obtained respectively.

Cardiac events that are classified as ventricular events following an atrial event can be reclassified as negligible events using the exemplary apparatus and methods described herein. For example, a cardiac signaling event is classified as a ventricular event within a time window following an atrial event. This negligible event will not be unintentionally used to influence cardiac pacing therapy, including, for example, ventricular sense-response pacing.

This invention relates to the field of medical device technology, and more particularly to an absorbable valve stent and a valve prosthesis including the absorbable valve stent. The absorbable valve stent includes an inner stent and an outer stent disposed on the outer periphery of the inner stent. The outer stent includes a main body segment and a valve annulus segment connected together. The main body segment is used to match the atrium, and the valve annulus segment is used to match the valve annulus. The bottom of the valve annulus segment is connected to the bottom of the inner stent via a connecting frame. The main body segment is composed of a first rod, which is either a non-fully absorbable rod or entirely made of a biodegradable absorbable material. The non-fully absorbable rod includes an inner core made of a non-biodegradable absorbable material and an outer sheath made of a biodegradable absorbable material that wraps around the inner core. After implantation, the support force of the main body segment on the atrium is weakened by the degradation and absorption of the outer sheath, or the support of the atrium is relieved by the complete degradation and absorption of the main body segment, allowing the atrium to restore normal contractility.

A method for predicting a recurrence of atrial fibrillation by an apparatus comprising a processor and a memory, according to an embodiment of the present invention, comprises the steps of: (a) generating target data including any one or more of geometric topological data, anatomical data, and electrophysiological data of the atrium of a patient; (b) preprocessing the generated target data; and (c) inputting the preprocessed target data into a prediction model to calculate and output a prediction value of a recurrence of atrial fibrillation for the patient and to learn the prediction value, wherein the target data is defined as a plurality of vertices and edges and is data having a basic structure of a three-dimensional polygon mesh including a plurality of triangular faces, which are minimum units of faces including the vertices and edges.

An implantable medical device configured to provide for an intracardiac function, the implantable medical device comprises a body, a sensor arrangement arranged on the body and configured to receive cardiac sense signals, and a processing circuitry operatively connected to the sensor arrangement. The processing circuitry is configured to process cardiac sense signals received using the sensor arrangement to detect a signal deflection potentially indicative of an atrial event caused by atrial activity to obtain an atrial detection, to detect a signal deflection indicative of a ventricular event caused by ventricular activity succeeding said atrial detection, to determine an atrial-ventricular interval representing a time between the atrial detection and the ventricular event, and to identify the atrial detection as valid or invalid based on the atrial-ventricular interval.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

A device for providing cardiac treatment at the left atrium of a patient's heart. The device includes a retention body and a prosthetic valve. The retention body has a shape that can be manipulated between a collapsed state and a normal or expanded state. First and second openings are defined at one side of the retention body, and a lower opening is defined at an opposite side. The prosthetic valve is carried by the retention body at the lower opening. The retention body is configured to engage a substantial portion of an interior surface of the left atrium, securing the prosthetic valve at a desired location relative to a native mitral valve (e.g., within the mitral valve or slightly spaced from the mitral valve). The first and second openings are sized and shaped so as to permit blood flow from the pulmonary veins into the interior region.

The transatrial septal catheter system for delivering a maneuverable sheath into the left atrium comprises three components. The first component is a three-segment needle guidewire (10) consisting of a distal needle (12) designed to abruptly flex relative to an attached loop guidewire segment (14) after fossa ovalis puncture and needle advancement. The distal guidewire loop is advanced into the left atrium, thereby maintaining the angled needle in a centered position relative to the loop for a non-invasive position while stabilizing the loop in the left atrium. A slender, proximal, ultra-rigid guidewire segment (16) is connected to the loop segment, which passes through the fossa ovalis and extends proximally for externalization to the femoral vein. This segment is ultra-rigid and significantly elongated to allow for catheter and device replacement. The guidewire serves as a support track on which the dilator (108) and sheath (100) can be advanced into the left atrium. This septal penetration system is uniquely forward-thinking and allows for the careful and iterative delivery of the dilator into the fossa ovalis, “tent-shaped” by a proximal sheath actuator that interacts with the dilator. The GW, now externalized at the proximal end, is then advanced to allow fossa ovalis puncture. After precise fossa ovalis puncture, the needle and coiled guidewire loop are further advanced into the left atrium. Using the proximal actuator (112), the dilator is advanced through the fossa ovalis into the left atrium via single-handed manipulation for individual dilator advancement and by rotating or actuating the sheath handle.

A system for treating atrial dysfunction, including heart failure and / or atrial fibrillation, that includes one or more pressurizing elements and control circuitry. The one or more pressurizing elements can comprise one or more balloons and can be configured to be positioned in the left atrium, and optionally the pulmonary artery, of a patient's heart. The one or more pressurizing elements can be coupled to one or more positioning structures that can be configured to position the one or more pressurizing elements in the left atrium, and optionally the pulmonary artery. The control circuitry can be configured to operate the one or more pressurizing elements to decrease or increase pressure and / or volume in the left atrium, and optionally the pulmonary artery, in accordance with different phases of the cardiac cycle. The control circuitry can be further configured to operate the one or more pressurizing elements to generate coordinated pressure modifications in the left atrium, and optionally the pulmonary artery.